Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Current status on microRNAs as biomarkers for ovarian cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Primary antibiotic resistance of Helicobacter pylori strains among adults and children in a tertiary referral centre in Lithuania

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A short history of microbial biofilms and biofilm infections

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Biofilms and host response - helpful or harmful

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Diagnosis of biofilm infections in cystic fibrosis patients

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Ovariecancerbehandling i Danmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Ovarian cancer (OC) is the most lethal gynecological malignancy in the Western world, and has a very poor prognosis, often due to late diagnosis and emergence of chemotherapy resistance. Therefore, there is an essential need for new diagnostic and prognostic markers that can improve and initiate more personalized treatment, eventually improving survival of the patients. MicroRNAs are small, non-coding RNA molecules, that post-transcriptionally regulate gene expression. Several studies have within the last decade shown that microRNAs are deregulated in OC and have potential as diagnostic and prognostic biomarkers for OC. Recently studies have also focused on microRNAs as predictors of chemotherapy responses and their potential as therapeutic targets. However, many of the published studies are difficult to interpret as a whole due to various methods of analysis. Future focus should be aimed at developing a general standardized analytical method, which can limit differences between studies thus allowing easier comparison across them. In addition, validation of studies in independent series that ideally should be histotype-specific is essential to determine the clinical role of microRNAs in different types of OC. In this review we summarize the current knowledge of microRNAs as potential biomarkers for OC, with focus on their clinical relevance.

OriginalsprogEngelsk
TidsskriftAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Vol/bind124
Udgave nummer5
Sider (fra-til)337-55
Antal sider19
ISSN0903-4641
DOI
StatusUdgivet - maj 2016

ID: 49472370